pravastatin has been researched along with Myocardial Ischemia in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (30.23) | 18.2507 |
| 2000's | 24 (55.81) | 29.6817 |
| 2010's | 6 (13.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alshehry, ZH; Barlow, CK; Barnes, EH; Chalmers, J; Giles, C; Hillis, GS; Huynh, K; Jayawardana, KS; Kingwell, BA; Kirby, A; Marschner, IC; McConville, MJ; Meikle, PJ; Mellett, NA; Mundra, PA; Nestel, PJ; Simes, J; Sullivan, DR; Thompson, P; Tonkin, AM; Wong, G; Woodward, M; Zoungas, S | 1 |
| Barnes, EH; Blankenberg, S; Colquhoun, DM; Hunt, D; Keech, AC; Marschner, IC; Nestel, P; Simes, J; Stewart, RA; Sullivan, DR; Thompson, P; Tonkin, A; West, M; White, HD; Zeller, T | 1 |
| Heritier, S; Hudson, HM; Lô, SN; Simes, RJ; Tonkin, AM | 1 |
| Seo, HS | 1 |
| Baek, SH; Cho, HJ; Jeon, HK; Kang, SM; Kim, HY; Lee, HY; Shin, JH | 1 |
| Braunwald, E; Cannon, CP; Giraldez, RR; Giugliano, RP; McCabe, CH; Mohanavelu, S; Murphy, SA | 1 |
| Chen, TT; Gao, CQ; Li, LB; Mi, WD; Wang, G | 1 |
| Canty, JM; Cimato, T; Lang, JK; Suzuki, G; Wang, W | 1 |
| Farmer, JA; Gotto, AM | 1 |
| Caleo, S; Eckermann, SD; Glasziou, PP; Hall, JP; Kirby, AC; Martin, AJ; Mulray, SE; Simes, RJ; Tonkin, AM; White, HD | 1 |
| Liakishev, AA | 1 |
| Agema, WR; Boer, JM; de Maat, MP; Feskens, EJ; Jukema, JW; Kastelein, JJ; Rabelink, TJ; van Boven, AJ; van der Wall, EE; Zwinderman, AH | 1 |
| Deedwania, PC | 1 |
| Bulhak, AA; Gonon, AT; Gourine, AV; Pernow, J; Sjöquist, PO; Valen, G | 1 |
| Bosmans, JM; Bridts, CH; Conraads, VM; De Clerck, LS; Schuerwegh, AJ; Stevens, WJ; Vrints, CJ; Wuyts, FL | 1 |
| Maron, DJ | 1 |
| Fonarow, GC | 1 |
| Brophy, JM; Costa, V | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Brown, BG | 1 |
| Rini, GB; Rizzo, M | 1 |
| Bairey Merz, CN; Cosin-Aguilar, J; Deedwania, P; Koylan, N; Luo, D; Ouyang, P; Piotrowicz, R; Schenck-Gustafsson, K; Sellier, P; Stein, JH; Stone, PH; Thompson, PL; Tzivoni, D | 1 |
| Gotto, AM | 1 |
| Tonkin, AM | 1 |
| Ichihara, K; Satoh, K | 1 |
| Hoshi, K; Ichihara, K; Nakai, T; Satoh, K; Yamato, A | 1 |
| Bruschke, AV; Crijns, HJ; Jukema, JW; Lie, KI; van Boven, AJ; Zwinderman, AH | 1 |
| Haastrup, B; Haghfelt, T | 1 |
| Kesäniemi, YA | 1 |
| Pitt, B | 1 |
| Azuma, N; Matsugane, T; Motohashi, K; Nishide, T; Nobuto, T; Suzuki, M; Yamane, S | 1 |
| Pedersen, TR | 1 |
| Hoshi, K; Ichihara, K; Satoh, K; Yamamoto, A | 1 |
| Kaminnaia, VI; Kaminnyĭ, AI; Konovalova, GG; Kukharchuk, VV; Lankin, VZ; Tikhaze, AK | 1 |
| Chisholm, DJ; Greenfield, JR | 1 |
| Mikhailidis, DP; Milionis, HJ; Rizos, E | 1 |
| Ishikawa, K; Kawabata, H; Ryomoto, T | 1 |
| Chou, TF; Lee, TM; Su, SF; Tsai, CH | 1 |
| Cesar, LA; Coelho, OR; Mansur, AP; Maranhão, M; Ramires, JA; Sposito, AC | 1 |
| Ishikawa, K; Kawabata, H; Nakagawa, K | 1 |
7 review(s) available for pravastatin and Myocardial Ischemia
| Article | Year |
|---|---|
In-hospital initiation of statin therapy in acute coronary syndromes: maximizing the early and long-term benefits.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Ischemia; Pravastatin; Pyrroles; Syndrome; Treatment Outcome | 2005 |
Statins, fracture risk, and bone remodeling: What is true?
Topics: Bone Remodeling; Female; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Male; Myocardial Ischemia; Osteoporosis; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 2006 |
Serum triglycerides and clinical benefit in lipid-lowering trials.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Myocardial Infarction; Myocardial Ischemia; Postmenopause; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Prevention. Who should take cholesterol-lowering drugs?
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Estrogen Replacement Therapy; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Myocardial Ischemia; Pravastatin | 1998 |
Results of recent trials on the progression of coronary artery disease and recurrent ischemic events: implications for interventional cardiology.
Topics: alpha-Linolenic Acid; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diet Therapy; Disease Progression; Humans; Myocardial Ischemia; Pravastatin | 1994 |
Statin trials and goals of cholesterol-lowering therapy after AMI.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Europe; Humans; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; United States | 1999 |
Smoking diminishes the beneficial effect of statins: observations from the landmark trials.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Gemfibrozil; Humans; Lovastatin; Myocardial Ischemia; Pravastatin; Risk Factors; Simvastatin; Smoking | 2001 |
14 trial(s) available for pravastatin and Myocardial Ischemia
| Article | Year |
|---|---|
Changes in plasma lipids predict pravastatin efficacy in secondary prevention.
Topics: Aged; Australia; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Prognosis; Risk Factors; Secondary Prevention; Treatment Outcome | 2019 |
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Predictive Value of Tests; Time Factors | 2013 |
Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study.
Topics: Aged; Biomarkers; Cholesterol, LDL; Down-Regulation; Dyslipidemias; Exercise Tolerance; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Prospective Studies; Quinolines; Recovery of Function; Republic of Korea; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Pravastatin; Pyrroles; Treatment Outcome | 2008 |
An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men.
Topics: Anticholesteremic Agents; Case-Control Studies; Coronary Angiography; Coronary Disease; Disease Progression; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Pravastatin; Statistics, Nonparametric | 2004 |
Effect of short-term treatment with pravastatin on cytokines and cytokine receptors in patients with chronic heart failure due to ischemic and nonischemic disease.
Topics: Aged; Case-Control Studies; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Humans; Inflammation Mediators; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Probability; Prospective Studies; Receptors, Cytokine; Sensitivity and Specificity; Treatment Outcome | 2005 |
Can pravastatin lower coronary event rate if HDL and LDL cholesterol are at low levels?
Topics: Acute Disease; Adult; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Incidence; Male; Myocardial Ischemia; Pravastatin; Risk Factors; Survival Rate; Treatment Outcome | 2004 |
Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pravastatin; Pyrroles; Sex Characteristics | 2007 |
Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S).
Topics: Adult; Aged; Anticholesteremic Agents; Australia; Cholesterol; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Myocardial Ischemia; New Zealand; Pravastatin; Scandinavian and Nordic Countries; Simvastatin; Survival Rate | 1995 |
Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group.
Topics: Angina Pectoris; Anticholesteremic Agents; Cardiovascular Agents; Cholesterol; Drug Therapy, Combination; Electrocardiography, Ambulatory; Humans; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Prospective Studies | 1996 |
Benefits beyond lipid-lowering.
Topics: Anticholesteremic Agents; Female; Humans; Male; Myocardial Ischemia; Odds Ratio; Placebos; Pravastatin | 1997 |
[Intensification in vivo of free radical oxidation of low density lipoproteins in plasma from patients with myocardial ischemia treated by HMG-CoA-reductase pravastatin and suppression of lipid peroxidation by ubiquinone Q10].
Topics: Antioxidants; Coenzymes; Double-Blind Method; Free Radicals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Ubiquinone | 2000 |
Effect of pravastatin on myocardial protection during coronary angioplasty and the role of adenosine.
Topics: Adenosine; Aminophylline; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Disease; Electrocardiography; Female; Hemodynamics; Humans; Hyperlipidemias; Lactates; Male; Middle Aged; Myocardial Ischemia; Pravastatin | 2001 |
Cholesterol lowering with statins reduces exercise-induced myocardial ischemia in hypercholesterolemic patients with coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Angiography; Coronary Disease; Exercise Test; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Simvastatin | 2001 |
22 other study(ies) available for pravastatin and Myocardial Ischemia
| Article | Year |
|---|---|
Semiparametric methods for multistate survival models in randomised trials.
Topics: Humans; Hydroxymethylglutaryl CoA Reductases; Incidence; Markov Chains; Models, Statistical; Myocardial Ischemia; Pravastatin; Randomized Controlled Trials as Topic; Research Design; Survival Analysis | 2014 |
Appropriate candidates for statin use in heart failure.
Topics: Cholesterol, LDL; Dyslipidemias; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Pravastatin; Quinolines | 2014 |
[Effects of pravastatin and granulocyto-colony stimulating factor in mobilizing endothelial progenitor cells in mice with myocardial ischemia].
Topics: Animals; Cell Movement; Endothelial Cells; Granulocyte Colony-Stimulating Factor; Leukocyte Count; Male; Mice; Myocardial Ischemia; Pravastatin; Stem Cells; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
Statins enhance clonal growth of late outgrowth endothelial progenitors and increase myocardial capillary density in the chronically ischemic heart.
Topics: Animals; Blotting, Western; Cells, Cultured; Endothelial Cells; Female; Flow Cytometry; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Immunophenotyping; Male; Microscopy, Fluorescence; Myocardial Ischemia; Pravastatin; Stem Cells; Swine | 2011 |
Reducing the risk for stroke in patients with myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Topics: Cholesterol; Clinical Trials as Topic; Cohort Studies; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Meta-Analysis as Topic; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Prospective Studies; Risk Assessment; Risk Factors; Scandinavian and Nordic Countries; Stroke; Survival Rate; Time; United States | 2002 |
Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?
Topics: Adult; Aged; Australia; Cholesterol; Cost-Benefit Analysis; Diagnosis-Related Groups; Double-Blind Method; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; New Zealand; Pravastatin; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis | 2002 |
[Results of clinical evidence: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hypertension; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; North America; Pravastatin; Randomized Controlled Trials as Topic | 2003 |
Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Pravastatin; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2004 |
Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level.
Topics: Administration, Oral; Animals; Blood Pressure; Cholesterol; Female; Fluorobenzenes; Heart; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Neutrophil Infiltration; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Peroxidase; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Swine | 2005 |
Statin wars following coronary revascularization--evidence-based clinical practice?
Topics: Aged; Drug Prescriptions; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Myocardial Ischemia; Myocardial Revascularization; Outpatients; Postoperative Care; Pravastatin; Retrospective Studies; Secondary Prevention; Simvastatin; Treatment Outcome | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression.
Topics: Africa; Angioplasty, Balloon, Coronary; Asia; Atorvastatin; Australia; Canada; Case Management; Cholesterol, LDL; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Europe; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Ischemia; New Zealand; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Simvastatin; South America; Stents; Tirofiban; Treatment Outcome; Tyrosine; United States | 2006 |
Statin therapy and the elderly: SAGE advice?
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Pravastatin; Pyrroles | 2007 |
Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts.
Topics: Adenosine Diphosphate; Animals; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Mitochondria, Heart; Myocardial Ischemia; Oxygen Consumption; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts.
Topics: Animals; Blood Pressure; Dogs; Enzyme Inhibitors; Female; Hydroxymethylglutaryl CoA Reductases; Lovastatin; Male; Mitochondria, Heart; Myocardial Ischemia; Pravastatin; Simvastatin; Time Factors | 1995 |
[Statin in the prevention of ischaemic heart disease].
Topics: Anticholesteremic Agents; Humans; Myocardial Ischemia; Pravastatin | 1997 |
[Coronary mortality lowered by 24%. Convincing results of the LIPID Study on Secondary Prevention].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Myocardial Ischemia; Pravastatin | 1998 |
Double filtration plasmapheresis maintains normal adhesion molecule levels.
Topics: Anticholesteremic Agents; Arteriosclerosis; Biomarkers; Cell Adhesion Molecules; Cholesterol; Disease Progression; Endothelium, Vascular; Filtration; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intercellular Adhesion Molecule-1; Myocardial Ischemia; Peripheral Vascular Diseases; Plasmapheresis; Pravastatin; Thrombomodulin; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 1998 |
[Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?].
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Dogs; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Contraction; Myocardial Ischemia; Myocardial Stunning; Myocardium; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Clinical trials and clinical practice--bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Evidence-Based Medicine; Humans; Hypertension; Hypoglycemic Agents; Metformin; Myocardial Ischemia; Practice Guidelines as Topic; Pravastatin; Risk Factors | 2000 |
Role of cardiac ATP-sensitive K+ channels induced by HMG CoA reductase inhibitor in ischemic rabbit hearts.
Topics: Adenosine Triphosphate; Animals; Enzyme Inhibitors; Glyburide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; In Vitro Techniques; Magnetic Resonance Spectroscopy; Myocardial Ischemia; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphorus Isotopes; Potassium Channels; Pravastatin; Rabbits | 2001 |
Effects of an HMG-CoA reductase inhibitor in combination with an ACE inhibitor or angiotensin II type 1 receptor antagonist on myocardial metabolism in ischemic rabbit hearts.
Topics: Adenosine Triphosphate; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiotonic Agents; Drug Combinations; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Myocardial Ischemia; Myocardium; NG-Nitroarginine Methyl Ester; Phosphates; Pravastatin; Rabbits; Receptor, Angiotensin, Type 1; Tetrazoles; Thiazepines | 2002 |